###begin article-title 0
Androgen regulation of the androgen receptor coregulators
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
The critical role of the androgen receptor (AR) in the development of prostate cancer is well recognized. The transcriptional activity of AR is partly regulated by coregulatory proteins. It has been suggested that these coregulators could also be important in the progression of prostate cancer. The aim of this study was to identify coregulators whose expression is regulated by either the androgens and/or by the expression level of AR.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 248 252 248 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRC1</italic>
###xml 254 258 254 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIF2</italic>
###xml 260 265 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIAS1</italic>
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIASx</italic>
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARIP4</italic>
###xml 281 286 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 288 300 288 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin</italic>
###xml 302 306 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB3</italic>
###xml 308 312 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1</italic>
###xml 314 317 311 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP</italic>
###xml 319 324 316 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT1</italic>
###xml 326 331 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NCoR1</italic>
###xml 333 336 330 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AES</italic>
###xml 338 347 335 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 349 353 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p300</italic>
###xml 355 360 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARA24</italic>
###xml 362 366 359 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LSD1</italic>
###xml 368 373 365 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAG1L</italic>
###xml 375 383 372 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gelsolin</italic>
###xml 385 395 382 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prohibitin</italic>
###xml 397 403 394 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD2C</italic>
###xml 405 411 402 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD1A</italic>
###xml 413 416 410 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK</italic>
###xml 418 423 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAK6 </italic>
###xml 427 433 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAGE11</italic>
We used empty vector and AR cDNA-transfected LNCaP cells (LNCaP-pcDNA3.1, and LNCaP-ARhi, respectively), and grew them for 4 and 24 hours in the presence of dihydrotestosterone (DHT) at various concentrations. The expression of 25 AR coregulators (SRC1, TIF2, PIAS1, PIASx, ARIP4, BRCA1, beta-catenin, AIB3, AIB1, CBP, STAT1, NCoR1, AES, cyclin D1, p300, ARA24, LSD1, BAG1L, gelsolin, prohibitin, JMJD2C, JMJD1A, MAK, PAK6 and MAGE11) was then measured by using real-time quantitative RT-PCR (Q-RT-PCR).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1</italic>
###xml 32 35 32 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP</italic>
###xml 37 40 37 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK</italic>
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 52 64 52 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin</italic>
###xml 114 123 111 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 125 133 122 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gelsolin</italic>
###xml 135 145 132 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prohibitin</italic>
###xml 147 153 144 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD1A</italic>
###xml 159 165 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD2C</italic>
###xml 345 348 342 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK</italic>
###xml 350 355 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 357 362 354 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1 </italic>
###xml 366 370 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP </italic>
###xml 409 421 406 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin</italic>
###xml 423 432 417 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclinD1 </italic>
###xml 436 444 430 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gelsolin</italic>
Five of the coregulators (AIB1, CBP, MAK, BRCA1 and beta-catenin) showed more than 2-fold induction and 5 others (cyclin D1, gelsolin, prohibitin, JMJD1A, and JMJD2C) less than 2-fold induction. Overexpression of AR did not affect the expression of the coregulators alone. However, overexpression of AR enhanced the DHT-stimulated expression of MAK, BRCA1, AIB1 and CBP and reduced the level of expression of beta-catenin, cyclinD1 and gelsolin.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
In conclusion, we identified 5 coactivators whose expression was induced by androgens suggesting that they could potentiate AR signaling. Overexpression of AR seems to sensitize cells for low levels of androgens.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 105 106 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 200 201 200 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 492 493 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 776 777 768 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 888 889 880 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 826 834 <span type="species:ncbi:9606">patients</span>
Prostate cancer is the most and second most common male malignancy in the USA, and Europe, respectively [1,2]. The androgen-dependence of the growth of prostate cancer has been known for a long time [3]. The importance of the androgens was recently, once again, demonstrated in a large randomized study. In the study the use of finasteride, an inhibitor of 5alpha-reductase, which converts testosterone into more potent 5alpha-dihydrotestosterone, was used for prevention of prostate cancer [4]. Almost 25% reduction in the prevalence of prostate cancer was observed in the treatment compared to a placebo arm. Due to the androgen dependence, the golden standard treatment for advanced prostate cancer has been androgen withdrawal (i.e. castration) for the last half century [5]. The treatment is palliative and although most patients respond to it, the disease will eventually progress [6]. Such tumors, emerging during the androgen withdrawal, are called hormone-refractory ones.
###end p 11
###begin p 12
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 360 372 360 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TMPRSS2:ERG </italic>
###xml 547 551 547 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERG </italic>
###xml 579 580 579 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 581 582 581 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 907 909 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1042 1045 1042 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AR </italic>
###xml 1051 1053 1051 1053 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1090 1093 1090 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AR </italic>
###xml 1156 1158 1156 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1159 1161 1159 1161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1339 1341 1336 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1342 1344 1339 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
The molecular mechanisms by which prostate cancer cells become resistant to endocrine therapy remain incompletely known. However, the key role of androgens and androgen receptor (AR), not just in early development but also in the progression of prostate cancer has now been demonstrated [7]. The recent finding on genetic rearrangement leading to formation of TMPRSS2:ERG fusion gene provides a model for molecular mechanisms how androgens act in promoting the early development of prostate cancer. Due to the rearrangement, the putative oncogene ERG becomes androgen regulated [8,9]. It has now also become apparent that the emergence of hormone-refractory prostate cancer is due to reactivation of AR-mediated signaling. It has been experimentally shown that overexpression on AR is required and it is sufficient to transform the growth of prostate cancer cells from androgen-dependence to -independence [10]. Furthermore, it has been shown that hormone-refractory tumors overexpress AR, and one-third of them contains amplification of the AR gene [11]. Mutations in the coding region of AR have also been found in antiandrogen treated prostate cancers [12,13]. And at least some of the mutations alter the sensitivity of the receptor to other steroid hormones or anti-androgens, such as 17 beta-estradiol (E2) or hydroxyflutamide (HF) [14,15].
###end p 12
###begin p 13
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
The transactivation of AR involves several coregulatory proteins [16,17]. Large number of coregulatory proteins have already been identified [18-20]. It has been suggested that changes in the expression of the coregulators may be involved in the development and progression of prostate cancer [18,21,22]. Since androgens and AR are known to be important in the prostate cancer tumorigenesis, it is possible that they also regulate the expression of the coregulators.
###end p 13
###begin p 14
###xml 137 142 137 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRC1 </italic>
###xml 149 155 149 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NCOA1 </italic>
###xml 188 193 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIF2 </italic>
###xml 200 206 200 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NCOA2 </italic>
###xml 239 245 239 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIAS1 </italic>
###xml 277 284 277 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT, 1</italic>
###xml 287 293 287 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIASx </italic>
###xml 300 306 300 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIAS2 </italic>
###xml 347 353 347 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARIP4 </italic>
###xml 360 373 360 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAD54L2 RAD54</italic>
###xml 382 395 382 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. cerevisiae</italic>
###xml 399 405 399 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 437 450 437 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin </italic>
###xml 457 464 454 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1 </italic>
###xml 520 525 517 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB3 </italic>
###xml 532 538 529 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NCOA6 </italic>
###xml 571 576 568 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1 </italic>
###xml 583 589 580 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NCOA3 </italic>
###xml 622 626 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP </italic>
###xml 633 645 630 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CREBBP CREB </italic>
###xml 691 697 688 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT1 </italic>
###xml 759 764 756 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p300 </italic>
###xml 771 777 768 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EP300 </italic>
###xml 804 810 801 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARA24 </italic>
###xml 817 820 814 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAN</italic>
###xml 829 833 826 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 851 856 848 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LSD1 </italic>
###xml 894 899 891 896 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AOF2 </italic>
###xml 944 950 941 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAG1L </italic>
###xml 951 955 948 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCL2</italic>
###xml 992 1001 989 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gelsolin </italic>
###xml 1002 1006 999 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSN </italic>
###xml 1036 1043 1033 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD2C </italic>
###xml 1094 1101 1091 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD1A </italic>
###xml 1146 1150 1143 1147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK </italic>
###xml 1186 1193 1183 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAGE11 </italic>
###xml 1200 1208 1197 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAGEA11 </italic>
###xml 1268 1274 1265 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NCoR1 </italic>
###xml 1309 1313 1306 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AES </italic>
###xml 1349 1359 1346 1356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1 </italic>
###xml 1366 1371 1363 1368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND1</italic>
###xml 1374 1385 1371 1382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prohibitin </italic>
###xml 1386 1389 1383 1386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PHB</italic>
###xml 1395 1400 1392 1397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAK6 </italic>
###xml 1401 1404 1398 1401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p21</italic>
###xml 1405 1411 1402 1408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN1A</italic>
###xml 382 395 <span type="species:ncbi:4932">S. cerevisiae</span>
In order to identify AR coregulators whose expression is regulated by androgens, we measured the expression of 20 putative coactivators: SRC1 (alias NCOA1 nuclear receptor coactivator 1), TIF2 (alias NCOA2 nuclear receptor coactivator 2), PIAS1 (protein inhibitor of activated STAT, 1), PIASx (alias PIAS2 protein inhibitor of activated STAT, 2), ARIP4 (alias RAD54L2 RAD54-like 2 (S. cerevisiae)), BRCA1 (breast cancer 1, early onset), beta-catenin (alias CTNNB1 catenin (cadherin-associated protein), beta 1, 88 kDa), AIB3 (alias NCOA6 nuclear receptor coactivator 6), AIB1 (alias NCOA3 nuclear receptor coactivator 3), CBP (alias CREBBP CREB binding protein (Rubinstein-Taybi syndrome)), STAT1 (signal transducer and activator of transcription 1, 91 kDa), p300 (alias EP300 E1A binding protein p300), ARA24 (alias RAN, member RAS oncogene family), LSD1 (lysine-specific demethylase 1, alias AOF2 amine oxidase (flavin containing) domain 2), BAG1L (BCL2-associated athanogene, isoform 1L), gelsolin (GSN (amyloidosis, Finnish type)), JMJD2C (alias JHDM3C/GASC1 jumonji domain containing 2C), JMJD1A (alias JHMD2A jumonji domain containing 1A), MAK (male germ cell-associated kinase), MAGE11 (alias MAGEA11 melanoma antigen family A, 11) and 5 putative corepressors: NCoR1 (nuclear receptor co-repressor 1), AES (amino-terminal enhancer of split), cyclin D1 (alias CCND1), prohibitin (PHB) and PAK6 (p21(CDKN1A)-activated kinase 6) by using quantitative reverse transcription-PCR (Q-RT-PCR) in AR positive prostate cancer cell line LNCaP treated with different concentrations of DHT. To mimic the common overexpression of AR in hormone-refractory prostate cancer, we also stable transfected AR to LNCaP cell line. The LNCaP-ARhi cells express about 10-folds more AR mRNA and 3 to 4-folds more AR protein than that of the control (empty vector-transfected cell line: LNCaP-pcDNA3.1). The cell model was used to study whether the level of AR has an effect on the mRNA expression of the coregulators.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Cell culture protocols and transfections
###end title 16
###begin p 17
###xml 999 1000 997 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
pcDNA3.1(+) empty expression vector (Invitrogen Inc., Carlsbad, CA, USA) and pcDNA3.1(+) inserted with AR coding region were stable transfected into LNCaP (ATCC, Manassas, VA, USA) with Lipofectamine-Plus transfection reagent (Invitrogen Inc.). Transfected clones were selected with 400 mug/ml geneticin (G418) for 2 weeks. The mRNA level of AR was examined from purified clones using Northern blotting and Q-RT-PCR with Light-Cycler (Roche Inc., Mannheim, Germany). The protein level of AR was analyzed using Western blotting with anti-AR antibody (441, NeoMarkers-Lab Vision Corporation, Fremont, CA, USA). LNCaP-pcDNA3.1 (transfected with empty pcDNA3.1-vector as a control) and LNCaP-ARhi (transfected with AR cloned into pcDNA3.1+ vector) cell lines were cultured according to the ATCC protocol with the addition of Geneticin 200 mug/ml (Invitrogen Inc.). LNCaP-ARhi has about 10 times higher mRNA level of AR and 3 to 4 times higher protein level of AR than that of the LNCaP-pcDNA3.1 (Figure 1).
###end p 17
###begin p 18
Western blot analysis of AR in empty vector transfected (LNCaP-pcDNA3.1) and AR-cDNA transfected (LNCaP-ARhi) LNCaP cells. Cells were grown either in the absence or presence of DHT. Nuclear fraction of LNCaP-ARhi shows clearly higher AR expression than the control LNCaP-pcDNA3.1. The quantification of the bands by ImageJ is given below the bands.
###end p 18
###begin p 19
LNCaP-pcDNA3.1 and LNCaP-ARhi cells in the end of the exponential growing phase were divided in 1:4 ratio plates in RPMI1640 phenol free medium with 5% charcoal/dextran-treated (CCS) FBS (Hyclone Inc., South Logan, UT, USA), 1% glutamine (Invitrogen Inc.) and 1% penicillin-streptomycin (BioWhittaker Inc., Walkersville, MD, USA) for 4 days. The medium was then changed to phenol free RPMI1640 including 10% CCS-FBS (Hyclone Inc.), 1% Glutamine (Invitrogen Inc.), 1% Pest (Invitrogen Inc.) and 0, 0.1, 1.0, 10 or 100 nM DHT. The cells were harvested into TRIZOL reagent (Life Technologies Inc., Gaithersburg, MD, USA) after 4 h and 24 h, followed by total RNA isolation according to the manufactures protocol.
###end p 19
###begin title 20
RT-PCR
###end title 20
###begin p 21
###xml 728 730 725 727 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 742 747 739 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAK6 </italic>
###xml 758 765 755 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD1A </italic>
###xml 1042 1043 1038 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1520 1523 1516 1519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP</italic>
###xml 1550 1552 1546 1548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 30 33 <span type="species:ncbi:11866?0.5863095238095238|species:ncbi:12321?0.21726190476190477">AMV</span>
The cDNA was synthesized with AMV Reverse Transcriptase and oligo(dT)12-18 primer according to the manufacturer's protocol (Finnzymes, Espoo Finland). The standards were prepared mixing total RNA from untreated LNCaP cells and universal RNA (Clontech Laboratories, Inc., Mountain View, CA, USA) in a ratio of 1:5. After first strand cDNA synthesis, serial dilutions corresponding to 1000, 200, 40, 8, 1.6, 0.32, 0.064 mug of RNA pool were prepared and stored in aliquots. The PCR reactions were performed in LightCycler apparatus (Roche Inc.) using an LC Fast Start DNA SYBR Green I Kit (Roche Diagnostics, Mannheim, Germany). The final volume of each reaction was 20 mul containing 2 mul of cDNA sample (or standard), 4 mM MgCl2 (except for PAK6 (5 mM) and JMJD1A (3 mM)), 0.5 muM each primer, and 1x ready-to-use SYBR Green I reaction mix including Taq DNA polymerase, reaction buffer and a deoxynucleotide triphosphate mix. The cycling conditions were designed according to the manufacturer's guidelines which are given in additional file 1: primers' table. The primers were designed for amplifying regions of the mRNAs derived from different exons to avoid amplification of genomic DNA. The melting curve analysis with the LightCycler together with 1.5% agarose gel electrophoresis of the products were used to ensure that right size product without significant background was amplified in the reaction. The expression levels of the coregulators were normalized to the expression levels of TATA-box binding protein (TBP) as previously described [23].
###end p 21
###begin title 22
Western analysis
###end title 22
###begin p 23
###xml 235 239 235 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
Cytoplasmatic and nuclear proteins were isolated from subconfluent cells of LNCaP-ARhi. Proteins were separated in 10% SDS-PAGE gel followed by transfer to a membrane (Immobilon-P, Millipore Corp., Billerica, MA) using BIORAD transblot(R) semi-dry transfer cell (Bio-Rad Laboratories, Inc). After blocking in PBS 0.1% Tween 5% BSA (or 5% non-fat dry milk), the membranes were incubated with primary antibody (AR: dilution 1: 200 Androgen Receptor Ab-1 (AR441) Neomarkers, Fremont, CA; beta-catenin: dilution 1:2000 BD Transduction Laboratories, Inc.; MAK: dilution 1:500 MAK antibody (C-term), ABGENT San Diego, CA; CBP: dilution 1:1000, R&D Systems, Inc.) over night at +4degreesC. After washes and incubation with secondary antibody (DAKO A/S, Denmark) the bound antibody was visualized on autogradiography film using Western Blotting Luminol Reagent (Santa Cruz, Inc.) according to the manufacturer's protocol. Pan-actin antibody (dilution 1:1000 pan AB-5, clone ACTN05, Neomarkers, Fremont, CA;) was used as a reference.
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
Grubb's test was used to detect the outlier values in the repetitive runs for each gene. One-way ANOVA (Parametric) test with Bonferroni post-test was used to evaluate the statistical significance of the expression level's changes.
###end p 25
###begin title 26
Results
###end title 26
###begin p 27
###xml 299 302 299 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSA</italic>
###xml 362 363 362 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 366 370 366 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSA </italic>
To identify androgen regulated coregulators, empty vector transfected LNCaP (LNCaP-pcDNA3.1) was grown in different concentrations of DHT. The total RNA was then collected at two time points (4 h and 24 h). To confirm the success of the DHT stimulation, the expression of prostate-specific antigen (PSA), known androgen regulated gene was first measured (Figure 2). PSA was strongly induced by DHT (p < 0.0001 at 4 h and 24 h).
###end p 27
###begin p 28
###xml 211 215 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSA </italic>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP </italic>
###xml 318 321 318 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSA</italic>
###xml 322 326 322 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP </italic>
Expression of PSA in LNCaP-pcDNA3.1 and LNCaP-ARhi according to Q-RT-PCR. The cells were cultured in presence of DHT at different concentrations. After 4 and 24 hours, the cells were collected and expression of PSA and TBP mRNA was measured in triplicates by Q-RT-PCR. The bars and whiskers represent mean + S.E.M. of PSA/TBP values normalized against the 0 M of each time point.
###end p 28
###begin p 29
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRC1</italic>
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIF2</italic>
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIAS1</italic>
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIASx</italic>
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARIP4</italic>
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 72 84 72 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin</italic>
###xml 86 90 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB3</italic>
###xml 92 96 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1</italic>
###xml 98 101 95 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP</italic>
###xml 103 108 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT1</italic>
###xml 110 115 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NCoR1</italic>
###xml 117 120 114 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AES</italic>
###xml 122 131 119 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 133 137 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p300</italic>
###xml 139 144 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARA24</italic>
###xml 146 151 143 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LSD1 </italic>
###xml 155 161 152 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAG1L </italic>
###xml 247 253 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIASx </italic>
###xml 297 303 294 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 347 360 344 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin </italic>
###xml 404 409 398 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB3 </italic>
###xml 453 458 447 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1 </italic>
###xml 502 506 496 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP </italic>
###xml 550 560 544 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1 </italic>
###xml 604 610 598 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARA24 </italic>
###xml 657 663 651 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAG1L </italic>
###xml 760 764 754 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SRC1</italic>
###xml 766 770 760 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIF2</italic>
###xml 772 777 766 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIAS1</italic>
###xml 779 784 773 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARIP4</italic>
###xml 786 791 780 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STAT1</italic>
###xml 793 798 787 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NCoR1</italic>
###xml 800 803 794 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AES</italic>
###xml 805 810 799 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p300 </italic>
###xml 814 819 808 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LSD1 </italic>
Next, we screened expression of SRC1, TIF2, PIAS1, PIASx, ARIP4, BRCA1, beta-catenin, AIB3, AIB1, CBP, STAT1, NCoR1, AES, cyclin D1, p300, ARA24, LSD1 and BAG1L coregulators in triplicates (three independent Q-RT-PCRs' runs). Of the coregulators, PIASx (p = 0.0601 at 4 h and p = 0.6488 at 24 h), BRCA1 (p = 0.4172 at 4 h and p = 0.0377 at 24 h), beta-catenin (p = 0.0272 at 4 h and p = 0.4158 at 24 h), AIB3 (p = 0.0690 at 4 h and p = 0.1455 at 24 h), AIB1 (p = 0.0401 at 4 h and p = 0.2541 at 24 h), CBP (p = 0.0184 at 4 h and p = 0.0588 at 24 h), cyclin D1 (p = 0.2039 at 4 h and p = 0.4432 at 24 h), ARA24 (p = 0.0220 at 4 h and p = 0.2502 at 24 h) and BAG1L (p = 0.0359 at 4 h and p = 0.3981 at 24 h), showed dose dependent response to androgens, whereas SRC1, TIF2, PIAS1, ARIP4, STAT1, NCoR1, AES, p300 and LSD1 did not.
###end p 29
###begin p 30
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIASx</italic>
###xml 7 12 7 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 14 26 14 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin</italic>
###xml 28 32 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB3</italic>
###xml 34 38 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1</italic>
###xml 40 43 37 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP</italic>
###xml 45 54 42 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 56 62 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARA24 </italic>
###xml 66 72 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAG1L </italic>
###xml 158 166 155 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gelsolin</italic>
###xml 168 178 165 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prohibitin</italic>
###xml 180 186 177 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD2C</italic>
###xml 188 194 185 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD1A</italic>
###xml 196 199 193 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK</italic>
###xml 201 206 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAK6 </italic>
###xml 210 217 207 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAGE11 </italic>
###xml 254 255 251 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 260 261 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 402 406 399 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1</italic>
###xml 408 411 405 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP</italic>
###xml 413 416 410 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK</italic>
###xml 418 423 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 425 437 422 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin</italic>
###xml 439 448 433 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 450 458 444 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gelsolin</italic>
###xml 460 470 454 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prohibitin</italic>
###xml 472 478 466 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD1A</italic>
###xml 484 490 478 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD2C</italic>
###xml 498 499 492 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 545 554 539 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gelsolin </italic>
###xml 732 736 726 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1</italic>
###xml 738 741 732 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP</italic>
###xml 743 746 737 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK</italic>
###xml 748 753 742 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 759 772 753 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin </italic>
PIASx, BRCA1, beta-catenin, AIB3, AIB1, CBP, cyclin D1, ARA24 and BAG1L were selected for additional Q-RT-PCR runs in triplicates. In addition, expression of gelsolin, prohibitin, JMJD2C, JMJD1A, MAK, PAK6 and MAGE11 was measured in triplicates. Figures 3 and 4 show the expression pattern of these 16 coregulators upon DHT stimulation. The genes that showed significant dose dependent expression were AIB1, CBP, MAK, BRCA1, beta-catenin, cyclin D1, gelsolin, prohibitin, JMJD1A, and JMJD2C. Table 1 indicates the p-values of the sixteen genes. Gelsolin showed reduced and increased expression at 4 and 24 hour time points, respectively. Others exhibited an androgen-dependent increase in the expression of the mRNAs. However, only AIB1, CBP, MAK, BRCA1, and beta-catenin showed more than 2-folds induction after stimulation with DHT.
###end p 30
###begin p 31
p-values of the One-way ANOVA (Parametric) test
###end p 31
###begin p 32
p-values of the 16 genes were measured in triplicate in the second round analysis.
###end p 32
###begin p 33
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1</italic>
###xml 24 27 24 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP</italic>
###xml 29 32 29 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK</italic>
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 41 53 41 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin</italic>
###xml 55 64 52 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 66 75 63 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gelsolin </italic>
###xml 79 90 76 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prohibitin </italic>
The expression of AIB1, CBP, MAK, BRCA1, beta-catenin, cyclin D1, gelsolin and prohibitin in LNCaP-pcDNA3.1 and LNCaP-ARhi at 4 and 24 hours according to Q-RT-PCR. The measurements were done in triplicates. The bars and whiskers represent mean + S.E.M. of each gene against the TBP, normalized against the 0 M of each time point. p-values are given in Table 1.
###end p 33
###begin p 34
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD1A</italic>
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD2C</italic>
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAG1L</italic>
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PIASx</italic>
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAK6</italic>
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAGE11</italic>
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB3</italic>
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ARA24 </italic>
The expression of JMJD1A, JMJD2C, BAG1L, PIASx, PAK6, MAGE11, AIB3, and ARA24 in LNCaP-pcDNA3.1 and LNCaP-ARhi at 4 and 24 hours according to Q-RT-PCR. The measurements were done in triplicates. The bars and whiskers represent mean + S.E.M. of each gene against the TBP, normalized against the 0 M of each time point. p-values are given in Table 1.
###end p 34
###begin p 35
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSA </italic>
###xml 329 330 329 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
In order to evaluate the effect of the level of AR expression on the expression of the coregulators, we utilized LNCaP-based overexpression model (LNCaP-ARhi). The PSA response in the LNCaP-ARhi cell line at 24 hours was significantly (p < 0.0001) stronger than in the empty vector transfected cell line (LNCaP-pcDNA3.1) (Figure 2). PSA expression was stimulated already in 1 nM concentration in the LNCaP-ARhi, whereas the stimulation was evident in 10 nM in the LNCaP-pcDNA3.1.
###end p 35
###begin p 36
###xml 246 249 246 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK</italic>
###xml 251 254 251 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP</italic>
###xml 256 260 256 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1</italic>
###xml 266 271 266 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 313 325 313 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin</italic>
###xml 327 337 324 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1 </italic>
###xml 341 349 338 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gelsolin</italic>
###xml 435 436 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 441 442 438 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
None of the coregulators showed significant alterations in the expression in 0 M DHT between the LNCaP-pcDNA3.1 and LNCaP-ARhi. However, induction of expression in lower concentrations of DHT in LNCaP-ARhi compared to LNCaP-pcDNA3.1 was found in MAK, CBP, AIB1, and BRCA1. In contrast, the androgen regulation of beta-catenin, cyclin D1 and gelsolin, which was apparent in LNCaP-pcDNA3.1 at 24 h was less strong in LNCaP-ARhi (Figures 3 and 4).
###end p 36
###begin p 37
###xml 118 119 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
Western blot analyses of beta-catenin, CBP and MAK were in concordance with the Q-RT-PCR results (see additional file 2: WB analysis).
###end p 37
###begin title 38
Discussion
###end title 38
###begin p 39
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1</italic>
###xml 202 205 202 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP</italic>
###xml 207 210 207 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK</italic>
###xml 212 218 212 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 222 234 222 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin</italic>
###xml 294 303 291 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 305 313 302 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gelsolin</italic>
###xml 315 325 312 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prohibitin</italic>
###xml 327 333 324 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD1A</italic>
###xml 339 345 336 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD2C</italic>
We systematically studied the androgen regulation of the expression of twenty-five AR coregulators. 5 (20%) coregultators showed statistically significant over 2-fold induction by DHT. These were AIB1, CBP, MAK, BRCA1 and beta-catenin. In addition, expression of five (20%) other coregulators (cyclin D1, gelsolin, prohibitin, JMJD1A, and JMJD2C) was significantly, but less than 2-fold, induced by androgens.
###end p 39
###begin p 40
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1 </italic>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 546 551 546 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1 </italic>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 734 736 734 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 783 788 783 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1 </italic>
###xml 1079 1081 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1187 1191 1187 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1</italic>
AIB1 (Amplified in Breast Cancer 1) encodes for a well characterized protein with histone acetyltransferase activity. It is thought to be a nuclear receptor coactivator that interacts with various nuclear hormone receptors enhancing their transcriptional activity in a hormone dependent fashion. It is a member of the p160/steroid receptor coactivator (SRC) family and recruits p300/CBP-associated factor, with histone acetylation activity, and CBP (CREB binding protein) as a part of the transcription multisubunit coactivation complex [19,24]. AIB1 has been found to be amplified in about 10% of breast cancers [25]. Previous studies have indicated that estrogens might have a suppressive role in respect to the expression of AIB1 [26,27]. Here we found that at 4 hours time point AIB1 is nearly 2-fold induced by any concentration of DHT while at 24 hours time point a 4-fold induction was observed. The highest induction was at 1 nM DHT while at 10 nM the expression was declined. We used web-based TESS (Transcription Element Search Software) program and TRANSFAC database [28] to search for canonical binding sites for AR in the 2 kb upstream the transcription start site (TSS) of AIB1. The program identified several glucocorticoid receptor (GR) responsive elements (GREs) and two putative androgen responsive elements (AREs) at -527 and at -1291 bp from the TSS.
###end p 40
###begin p 41
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1</italic>
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP </italic>
###xml 305 309 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP </italic>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
Similarly to AIB1, CBP was nearly 2-folds induced at 4 hours time point by any concentration of DHT while at 24 hours time point a 4-folds induction can be observed, although such induction can be seen also in 10 nM DHT concentrated media. In contrast with our results, Comuzzi et al. have suggested that CBP expression is down-regulated after treating LNCaP cells with synthetic androgen methyltrienolone (R1881) for 48 hours at concentrations of 0.01 nM and 1 nM [29].
###end p 41
###begin p 42
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK </italic>
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 223 227 223 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK </italic>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 674 676 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 706 710 706 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK </italic>
###xml 801 805 801 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK </italic>
###xml 868 872 868 872 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK </italic>
###xml 963 965 963 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1021 1025 1021 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK </italic>
###xml 151 155 <span type="species:ncbi:10090">mice</span>
MAK (Male Germ Cell-Associated Kinase) is a recently identified AR coactivator [30] that initially has been found to be strongly androgen-regulated in mice kidney [31]. In addition, it has previously been demonstrated that MAK is transcriptionally induced by DHT in LNCaP cells showing 9-fold induction by 10 nM DHT at 24 hours [32]. This is confirmed by our finding of 6.5-fold induction at 24 hours time point by 10 nM DHT. MAK has been found to be associated with AR and being corecruited in the transcriptional complex enhancing AR activity. Furthermore the modulation of its expression strongly alters the vitality of the cells affecting AR pathway mediated signaling [30]. Jia et al. have shown that MAK promoter is a direct target of AR and identified putative ARE sites within the promoter of MAK (about -3500 bp from the TSS), and that AR is recruited to the MAK promoter after DHT stimulation according to chromatin immunoprecipitation (ChIP) analysis [33]. Altogether the data indicates that the expression of MAK is regulated by androgens and since it functions as an AR co-activator, it forms a putative feedback loop augmenting the effects of androgens.
###end p 42
###begin p 43
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 473 478 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 521 527 521 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
BRCA1 (breast cancer 1) is a well characterized gene in breast cancer since mutations in this gene are responsible of at least 40% of inherited breast cancers and more than 80% of inherited ovarian cancers [34,35]. BRCA1 is also an AR coactivator that has been demonstrated to enhance AR transactivation in prostate and breast cancer cell lines with a synergistic effect with other p160 coactivators [36]. Our data shows an androgen-mediated induction of the expression of BRCA1. It has previously been demonstrated that BRCA1 is an estrogen induced gene in breast and ovarian cancer cells [37,38].
###end p 43
###begin p 44
###xml 169 171 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 361 363 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 364 366 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 526 528 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 529 531 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 632 634 623 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 635 637 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 658 671 649 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin </italic>
beta-catenin is an adherens junction protein with altered expression in various tumor types. Its fundamental role as a multifunctional oncoprotein has been established [39]. The gene encodes for a protein that interacts with AR in close proximity with p160 coactivator family and it is thought to be important for the formation of the AR transcription complex [40,41]. There is some evidence that AR could also have an important role as a scaffolding protein in beta-catenin translocation from the cytoplasm into the nucleus [42-44]. beta-catenin has been shown to augment AR transcriptional function in a ligand-dependent fashion [43,45]. Here we show that beta-catenin is induced up to 2.5-folds at 24 hours time point, already at a concentration of 0.1 nM of DHT. The induction reaches then the 3-folds and declines at 2-folds at 100 nM showing a significant androgen regulation.
###end p 44
###begin p 45
###xml 49 58 49 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1</italic>
###xml 60 68 60 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gelsolin</italic>
###xml 70 80 70 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">prohibitin</italic>
###xml 82 89 82 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD1A </italic>
###xml 93 100 93 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JMJD2C </italic>
In addition to the above mentioned coregulators, cyclin D1, gelsolin, prohibitin, JMJD1A and JMJD2C showed a significant dose dependent effect in their expression level mainly at 24 hours time point. However, the induction was very mild, less than 2-fold, suggesting either only weak androgen effect or secondary mechanisms for the induction.
###end p 45
###begin p 46
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 255 256 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 788 793 788 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">e.g. </italic>
###xml 797 800 797 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PSA</italic>
###xml 951 954 951 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK</italic>
###xml 956 959 956 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP</italic>
###xml 965 971 965 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1085 1089 1085 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK </italic>
###xml 1093 1097 1093 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP </italic>
###xml 1146 1152 1146 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1 </italic>
###xml 1270 1282 1270 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin</italic>
###xml 1284 1294 1281 1291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1 </italic>
###xml 1298 1306 1295 1303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gelsolin</italic>
###xml 1674 1676 1671 1673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
It has been demonstrated that AR is commonly overexpressed in hormone-refractory prostate cancer [11,46,47]. In addition, it has been shown that the overexpression is capable to transform androgen dependent growth of prostate cancer cell to independence [9]. To study the effect of AR overexpression, we stable transfected AR to LNCaP cell line leading to 3 to 4-fold increased expression of AR. The growth of LNCaP-ARhi was stimulated on lower concentrations of androgens than the growth of LNCaP-pcDNA3.1 (unpublished data). None of the coregulators were up- or downregulated by the level of AR alone since there was no significant difference in the expression of the coregulators at 0 M of DHT. Instead, the overexpression of AR seems to sensitize cells to androgens. This was evident e.g. for PSA, which was significantly upregulated more and in lower concentrations of DHT in LNCaP-ARhi than in LNCaP-pcDNA3.1 cells. Similarly, the expression of MAK, CBP, and BRCA1 was increased more in LNCaP-ARhi than in LNCaP-pcDNA3.1, and, at least, a 10-fold sensitization was observed. For MAK and CBP this was apparent in 4 h time point, whereas for BRCA1 at 24 h time point. Interestingly, the increased expression of AR did not affect all androgen-regulated coregulators. beta-catenin, cyclin D1 and gelsolin, which showed androgen-regulation in LNCaP-pcDNA3.1 at 24 hours were not regulated by androgens in LNCaP-ARhi. The data suggest that the AR overexpression has distinct effects on different target genes. It should be recognized that during the androgen withdrawal, there are still adrenal androgens left. For example, the DHT concentration is only partially depleted [48]. Thus, the genes that are regulated in reduced DHT concentrations due to AR overexpression might be important in the progression of prostate cancer during the hormonal therapy.
###end p 46
###begin p 47
###xml 348 352 348 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AIB1</italic>
###xml 354 357 354 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CBP</italic>
###xml 359 362 359 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAK</italic>
###xml 364 369 364 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BRCA1</italic>
###xml 371 383 371 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin</italic>
The effects of androgens on gene expression were measured at two time points, 4 h and 24 h. The 4 h time points represent a time interval where direct effects of androgens administration should be seen, although the effect can be mild. On the other hand, also secondary mechanisms can already be activated at 24 hours time point. All coregulators (AIB1, CBP, MAK, BRCA1, beta-catenin) that were induced more than 2-fold by DHT, showed the induction already at 4 time point in one or both cells lines (LNCaP-pcDNA3.1 and LNCaP-ARhi) suggesting direct regulation. Whereas, coregulators with lower-level of induction showed the effect variably in 4 and 24 hour points, which may also suggest secondary mechanisms of androgen regulation.
###end p 47
###begin title 48
Conclusion
###end title 48
###begin p 49
In conclusion, by systematic measurement of 25 AR coregulators, we identified 5 coregulators whose expression seems to be significantly androgen-regulated indicating that they could be a part of positive feedback mechanisms potentiating the AR signaling. Overexpression of AR seems to sensitize cells in terms of androgen regulation but the effect is gene-specific since not all androgen-regulated genes were up-regulated in AR overexpressing model.
###end p 49
###begin title 50
Competing interests
###end title 50
###begin p 51
The authors declare that they have no competing interests.
###end p 51
###begin title 52
Authors' contributions
###end title 52
###begin p 53
AU: acquired the data through PCR, prepared the manuscript, analyzed and interpreted the data. KW: made the cell-culture work. HM: supported the PCR work. HS: established the AR overexpression cell lines. TV: designed the study, helped preparing the manuscript and analyzing and interpreting the data. All authors read and approved the final manuscript.
###end p 53
###begin title 54
Pre-publication history
###end title 54
###begin p 55
The pre-publication history for this paper can be accessed here:
###end p 55
###begin p 56

###end p 56
###begin title 57
Supplementary Material
###end title 57
###begin title 58
Additional file 1
###end title 58
###begin p 59
###xml 17 18 17 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Additional Table 1 - primers' sequences and cycling conditions. primers' sequences and cycling conditions.
###end p 59
###begin p 60
Click here for file
###end p 60
###begin title 61
Additional file 2
###end title 61
###begin p 62
###xml 18 19 18 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Additional Figure 1. Western blot analysis. Western analysis of beta-catenin, CBP, and MAK in LNCaP-ARhi cells treated with different concentrations of DHT.
###end p 62
###begin p 63
Click here for file
###end p 63
###begin title 64
Acknowledgements
###end title 64
###begin p 65
The authors wish to acknowledge Ms. Mariitta Vakkuri for the technical assistance. This work was supported by Academy of Finland, Cancer Society of Finland, Reino Lahtikari Foundation, Sigrid Juselius Foundation, Finnish Cultural Foundation, the Medical Research Fund of Tampere University Hospital, and the European Union FP6, CANCURE Programme (Contract Number: MEST-CT-2005-020970).
###end p 65
###begin article-title 66
The changing face of prostate cancer
###end article-title 66
###begin article-title 67
Cancer incidence and mortality in Europe, 2004
###end article-title 67
###begin article-title 68
Role of androgens in prostatic cancer
###end article-title 68
###begin article-title 69
The influence of finasteride on the development of prostate cancer
###end article-title 69
###begin article-title 70
Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate 1941
###end article-title 70
###begin article-title 71
Carcinoma of the prostate
###end article-title 71
###begin article-title 72
Alterations of androgen receptor in prostate cancer
###end article-title 72
###begin article-title 73
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
###end article-title 73
###begin article-title 74
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer
###end article-title 74
###begin article-title 75
Molecular determinants of resistance to antiandrogen therapy
###end article-title 75
###begin article-title 76
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer
###end article-title 76
###begin article-title 77
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist
###end article-title 77
###begin article-title 78
Androgen receptor gene mutations in hormone-refractory prostate cancer
###end article-title 78
###begin article-title 79
Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide
###end article-title 79
###begin article-title 80
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome
###end article-title 80
###begin article-title 81
Molecular communication between androgen receptor and general transcription machinery
###end article-title 81
###begin article-title 82
Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications
###end article-title 82
###begin article-title 83
Expression and function of androgen receptor coactivators in prostate cancer
###end article-title 83
###begin article-title 84
Androgen receptor coregulators and their involvement in the development and progression of prostate cancer
###end article-title 84
###begin article-title 85
Androgen receptor corepressors and prostate cancer
###end article-title 85
###begin article-title 86
Androgen receptor as a target in androgen-independent prostate cancer
###end article-title 86
###begin article-title 87
###xml 58 63 <span type="species:ncbi:9606">human</span>
Different expression of androgen receptor coactivators in human prostate
###end article-title 87
###begin article-title 88
Expression of androgen receptor coregulators in prostate cancer
###end article-title 88
###begin article-title 89
Androgen receptor (AR) coregulators: An overview
###end article-title 89
###begin article-title 90
AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer
###end article-title 90
###begin article-title 91
A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells
###end article-title 91
###begin article-title 92
Selective estrogen receptor modulators 4-hydroxytamoxifen and raloxifene impact the stability and function of SRC-1 and SRC-3 coactivator proteins
###end article-title 92
###begin article-title 93
TESS: Transcription Element Search Software on the WWW
###end article-title 93
###begin article-title 94
The androgen receptor coactivator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer
###end article-title 94
###begin article-title 95
Male germ cell-associated kinase, a male-specific kinase regulated by androgen, is a coactivator of androgen receptor in prostate cancer cells
###end article-title 95
###begin article-title 96
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
Androgen regulation of MAK mRNAs in mouse kidney
###end article-title 96
###begin article-title 97
###xml 18 23 <span type="species:ncbi:9606">human</span>
Identification of human male germ cell-associated kinase, a kinase transcriptionally activated by androgen in prostate cancer cells
###end article-title 97
###begin article-title 98
Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus
###end article-title 98
###begin article-title 99
The genetics of breast cancer susceptibility
###end article-title 99
###begin article-title 100
The functions of breast cancer susceptibility gene 1 (BRCA1) product and its associated proteins
###end article-title 100
###begin article-title 101
Breast cancer susceptibility gene 1 (BRCA1) is a coactivator of the androgen receptor
###end article-title 101
###begin article-title 102
###xml 41 46 <span type="species:ncbi:9606">human</span>
Hormone-dependent regulation of BRCA1 in human breast cancer cells
###end article-title 102
###begin article-title 103
Estrogen upregulation of BRCA1 expression with no effect on localization
###end article-title 103
###begin article-title 104
Beta-catenin and cancer
###end article-title 104
###begin article-title 105
beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription
###end article-title 105
###begin article-title 106
Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor
###end article-title 106
###begin article-title 107
Liganded androgen receptor interaction with beta-catenin
###end article-title 107
###begin article-title 108
Linking beta-catenin to androgen-signaling pathway
###end article-title 108
###begin article-title 109
The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli
###end article-title 109
###begin article-title 110
beta-catenin affects androgen receptor transcriptional activity and ligand specificity
###end article-title 110
###begin article-title 111
###xml 71 76 <span type="species:ncbi:9606">human</span>
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
###end article-title 111
###begin article-title 112
###xml 97 102 <span type="species:ncbi:9606">human</span>
Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays
###end article-title 112
###begin article-title 113
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer
###end article-title 113

